Circulating tumor DNA profiling of advanced biliary tract cancers

Kabir Mody, Pashtoon M. Kasi, Ju Dong Yang, Phani Keerthi Surapaneni, Tanios Bekaii-Saab, Daniel H. Ahn, Amit Mahipal, Mohamad B. Sonbol, Jason S. Starr, Ali Roberts, Rebecca Nagy, Richard Lanman, Mitesh J. Borad

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


PURPOSE Recent advances in molecular diagnostic technologies have allowed for the evaluation of solid tumor malignancies via noninvasive blood sampling, including circulating tumor DNA (ctDNA) profiling. We sought to characterize the ctDNA genomic alteration landscape in patients with biliary tract cancers (BTCs). PATIENTS AND METHODS From January 2015 to February 2018, 124 patients with BTC at the Mayo Clinic Comprehensive Cancer Center underwent ctDNA testing using a clinically available assay. The majority of samples (n = 122) were tested using the 73-gene panel that includes somatic genomic targets, including complete or critical exon coverage in 30 and 40 genes, respectively, and in some, amplifications, fusions, and indels. RESULTS A total of 138 samples were included, with approximately 70% of patients having intrahepatic BTC. All patients had locally advanced or metastatic BTC. Samples with one or more alterations, when variants of unknown significance were excluded, numbered 105 (76%). Each sample contained, on average, three alterations with a median allelic fraction of 0.52%. The overall landscape of alterations is summarized in Figures 1 and 2. After excluding variants of unknown significance, therapeutically relevant alterations were observed in 76 patients (55%), including BRAF mutations, ERBB2 amplifications, FGFR2 fusions, FGFR2 mutations, and IDH1 mutations seen in 21% of patients. A different spectrum of alterations was observed in patients with early-onset BTC (younger than age 50 years) compared with older patients (older than age 50 years). CONCLUSION Data on ctDNA in BTC is currently limited. Our study, the largest cohort reported to date to our knowledge, demonstrates the feasibility of ctDNA testing in this disease. We provide a foundation upon which the field can continue to grow.

Original languageEnglish (US)
JournalJCO Precision Oncology
StatePublished - Jan 1 2019

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Circulating tumor DNA profiling of advanced biliary tract cancers'. Together they form a unique fingerprint.

Cite this